Lv1
60 积分 2025-01-19 加入
Abstract PS3-07: SHR-A1811 as Neoadjuvant Treatment in Patients with HR-Positive, HER2-low Breast Cancer: The first-stage results from an open-label, single-arm, two-stage, phase II clinical trial
6小时前
已关闭
Changes of immunohistochemical biomarkers before and after neoadjuvant chemotherapy in breast cancer and their prognosis
15小时前
已完结
Targeting systemic and gut microbial metabolism in ER+ breast cancer
1个月前
已完结
Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
1个月前
已完结
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer
1个月前
已完结
Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?
3个月前
已完结
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
6个月前
已完结
Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in patients receiving Neoadjuvant Chemotherapy for HR-Positive HER2-Negative Breast Cancer
6个月前
已完结
Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in patients receiving Neoadjuvant Chemotherapy for HR-Positive HER2-Negative Breast Cancer
6个月前
已关闭
Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping
8个月前
已完结
皖公网安备34019202002308
